Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2763-2768

  Berruti, A ^a   Zola, P ^a   Buniva, T ^a   Bau M G ^a   Farris, A ^b   Sarobba, M G ^b   Bottin, A ^c   Tampellini, M ^a   Durando, A ^d   Destefanis, M ^e   Monzeglio, C ^f   Moro, G ^g   Sussio, M ^h   Perroni, D ⁱ   Dogliotti, Luigi ^a,j  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e Oncologia Ospedale di Alba   (Italy)

^f Ospedale Martini   (Italy)

^g Ospedale di Biella   (Italy)

^h Ospedale di Savigliano   (Italy)

ⁱ Ospedale di Cuneo   (Italy)

^j SAN LUIGI GONZAGA HOSPITAL   (Italy)

more..

Author keywords

Breast neoplasms; Maintenance endocrine therapy; Metastatic disease; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; ESTROGEN RECEPTOR; LONIDAMINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS; OBSERVATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; INDAZOLES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0030748001     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. La Vecchia C, Negri E, Decarli A, Fasoli M and Cislaghi C: Cancer mortality in Italy: an overview of age-specific and age-standardized trends from 1955 to 1984. Tumori 76: 87-166, 1990.
2. Hayes DF, Henderson C and Shapiro C: Treatment of metastatic breast cancer: present and future prospects. Seminars in Oncology 22: 5-21, 1995.
3. Overmoyer BA: Chemotherapeutic palliative approaches in the treatment of breast cancer. Seminars in Oncology 22: 2-9, 1995.
4. Anderson J, Cain K and Gelber R: Analysis of survival by tumor response. J Clin Oncol 1: 710-719, 1983.
5. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Arquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M and Perroni D: Lonidamine significantly increases the activity of epirubicin in advanced breast cancer patients. Results from a multicenter prospective randomized trial. J Clin Oncol 14: 1165-1172, 1996.
6. Gregory WM, Smith P, Richards MA, Twelves CJ, Knight RK and Rubens RD: Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer 68: 988-995, 1993.
7. The Australian and New Zealand Breast Cancer Trials Group: A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4: 186-193, 1986.
8. Clark GM, Sledge GW, Osborne CK and MeGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55-617 1987.
9. Falkson G, Holcroft C, Gelman RS, Tormey DC, Woher JM and Cummings FJ: Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13: 1453-14587 1995.
10. Koenders PG, Beex LV, Kloppenborg PW, Smals AG and Benraad TJ: Human breast cancer: survival from first metastasis. Breast Cancer Res Treat 21: 173-1807 1992.
11. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap Hwee-Y, Gutterman JU and Blumenschein GR: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552-1562, 1979.
12. Zinser JW, Hortobagyi GN, Buzdar AU, Smith T and Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773-782, 1987.
13. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G and Dogliotti L: Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A: 2082-2084, 1994.
14. Ahmann FR, Jones SE and Moon TE: The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 37: 116-1227 1988.
15. Houston SJ, Richards MA, Bentley AE, Smith P and Rubens RD: The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer 29A: 1513-1518, 1993.
16. Nie NH, Hull CH and Jeakins JG: Statistical package for the social sciences. SPSS Inc Chicago IL USA 1988.
17. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P., Demicheli R and Valagussa P: Drugs ten year later: Epirubicin. Ann Oncol 4: 359-369, 1993.
18. Coleman RE, Whitaker KD, Moss DW and Null O: Biochemical monitoring predicts response in bone metastases to treatment. Br J Cancer 58: 621-625, 1988.
19. Berruti A, Osella G, Raucci CA, Roncari A and Dogliotti L: Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases. Oncology 50: 218-221, 1993.
20. Dixon AR, Jackson L, Chan SY, Badley RA and Blarney RW: Continuous chemotherapy in responsive metastatic breast cancer: a role for tumor markers? Br J Cancer 68: 181-185, 1993.
21. Jordan CV, Jeng Meei-H, Jiang Shun-Y, Yingling J and Stella AL: Hormonal strategies for breast cancer: a new focus on the estrogen receptor as a therapeutic target. Seminars in Oncology 19: 299-307, 1992.
22. Boccardo F, Ruhagotti A, Perrotta A. Amoroso D, Balestrero M, De Matteis A, Zola P, Sismondi P, Francini G, Petrioli R, Sassi M, Pacini P and Galligioni E: Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric italian study. Ann Oncol 5: 337-342, 1994.
23. Beltran M, Alonso MC, Ojeda MB, Izquierdo A, Ferrer J, Pico C, Anglada L, Catalan G, Batiste-Alentorn E, Tusquets I, Rifa J and Balil AM: Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients. Ann Oncol 2: 495-499, 1991.